Abstract
A revolutionary shift in healthcare has been sparked by the development of 3D printing, propelling
us into an era replete with boundless opportunities for personalized DDS (Drug Delivery Systems). Precise
control of the kinetics of drug release can be achieved through 3D printing, improving treatment efficacy and
patient compliance. Additionally, 3D printing facilitates the co-administration of multiple drugs, simplifying
treatment regimens. The technology offers rapid prototyping and manufacturing capabilities, reducing development
timelines and costs. The seamless integration of advanced algorithms and artificial neural networks (ANN)
augments the precision and efficacy of 3D printing, propelling us toward the forefront of personalized
medicine. This comprehensive review delves into the regulatory frontiers governing 3D printable drug delivery
systems, with an emphasis on adhering to rigorous safety protocols to ensure the well-being of patients by
leveraging the latest advancements in 3D printing technologies powered by artificial intelligence. The
paradigm promises superior therapeutic outcomes and optimized medication experiences and sets the stage for
an immersive future within the Metaverse, wherein healthcare seamlessly converges with virtual environments
to unlock unparalleled possibilities for personalized treatments.
Keywords:
3D printing, metaverse, personalized medicine, algorithms, artificial neural networks, selective laser sintering, drug delivery system, healthcare.
[3]
Tang Y, Dehaghani MR, Wang GG. Review of transfer learning in modeling additive manufacturing processes. Addit Manuf 2023; 61: 103357.
[24]
Rahman M, Kamal MA. Cancer nanotherapeutics: Targeted medicine, therapeutic vaccination and challenges with cancer nanomedicines. InSeminars in cancer biology 2021; 69: 1-4.
[36]
Venkatesan J, Anil S, Murugan SS. 3D bioprinted alginate-based biomaterials for bone tissue engineering. J 3D print med 2020; 14(4): 175-9.
[80]
Loh QL, Choong C. Three-dimensional scaffolds for tissue engineering applications: Role of porosity and pore size. Tissue Eng Part B Rev 2013; 19(6): 485-502.
[83]
Des Rieux A, Pourcelle V, Cani PD, Marchand-Brynaert J, Préat V. Targeted nanoparticles with novel non-peptidic ligands for oral delivery. Adv Drug Deliv Rev 2013; 15,65(6): 833-44.
[84]
FDA U. Technical considerations for additive manufactured medical devices: guidance for industry and Food and Drug Administration staff. 2017.
[85]
Samiei N. Recent trends on applications of 3D printing technology on the design and manufacture of pharmaceutical oral formulation: a mini review. Beni Suef Univ J Basic Appl Sci 2020; 9(1): 1-2.
[88]
Arya RK, Bisht D, Dhondiyal K, et al. Role of 3D Printing in Pharmaceutical Industry. In: New Horizons for Industry 40 in Modern Business. Cham: Springer International Publishing 2023; pp. 273-94.
[102]
Gross BC, Erkal JL, Lockwood SY, Chen C, Spence DM. Evaluation of 3D printing and its potential impact on biotechnology and the chemical sciences. Anal Chem 2014; 86(7): 3240-53.